Nonalcoholic Fatty Liver Disease

Overview

Journal Handb Exp Pharmacol

Specialty Pharmacology

Date 2020 Mar 19

PMID 32185502

Citations 6

Authors

Lingling Ding

Yvonne Oligschlaeger

Ronit Shiri-Sverdlov

Tom Houben

Affiliations

Soon will be listed here.

Abstract

Nonalcoholic fatty liver disease (NAFLD) is considered the hepatic manifestation of the metabolic syndrome (MetS) and comprises one of the largest health threats of the twenty-first century. In this chapter, we review the current state of knowledge of NAFLD and underline the striking similarities with atherosclerosis. We first describe current epidemiological data showing the staggering increase of NAFLD numbers and its related clinical and economic costs. We then provide an overview of pathophysiological hepatic processes in NAFLD and highlight the systemic aspects of NAFLD that point toward metabolic crosstalk between organs as an important cause of metabolic disease. Finally, we end by highlighting the currently investigated therapeutic approaches for NAFLD, which also show strong similarities with a range of treatment options for atherosclerosis.

Citing Articles

Mediated Targeting // to Accelerate Thyroid Stimulating Hormone-Induced Hepatic Steatosis.

Li J, Ge Y, Chai Y, Kou C, Sun T, Liu J Hepat Med. 2024; 16:91-104.

PMID: 39583015 PMC: 11583786. DOI: 10.2147/HMER.S481687.

Research progress and application of liver organoids for disease modeling and regenerative therapy.

Hu Y, Geng Q, Wang L, Wang Y, Huang C, Fan Z J Mol Med (Berl). 2024; 102(7):859-874.

PMID: 38802517 PMC: 11213763. DOI: 10.1007/s00109-024-02455-3.

Comparison of efficacy of anti-diabetics on non-diabetic NAFLD: A network meta-analysis.

Jin D, Cui Z, Jin S, Zhou T, Guo B, Gao P Front Pharmacol. 2023; 13:1096064.

PMID: 36699084 PMC: 9868463. DOI: 10.3389/fphar.2022.1096064.

Synergistic delivery of resveratrol and ultrasmall copper-based nanoparticles by aptamer-functionalized ultrasound nanobubbles for the treatment of nonalcoholic fatty liver disease.

Guo X, Huang Z, Chen J, He K, Lin J, Zhang H Front Physiol. 2022; 13:950141.

PMID: 36160874 PMC: 9502034. DOI: 10.3389/fphys.2022.950141.

Associations of Sex Steroids and Sex Hormone-Binding Globulin with Non-Alcoholic Fatty Liver Disease: A Population-Based Study and Meta-Analysis.

Zhang X, Mou Y, Aribas E, Amiri M, Nano J, Bramer W Genes (Basel). 2022; 13(6).

PMID: 35741728 PMC: 9223113. DOI: 10.3390/genes13060966.

References

Abdelmalek M . NAFLD: The clinical and economic burden of NAFLD: time to turn the tide. Nat Rev Gastroenterol Hepatol. 2016; 13(12):685-686. DOI: 10.1038/nrgastro.2016.178. View

Ackerman Z, Oron-Herman M, Grozovski M, Rosenthal T, Pappo O, Link G . Fructose-induced fatty liver disease: hepatic effects of blood pressure and plasma triglyceride reduction. Hypertension. 2005; 45(5):1012-8. DOI: 10.1161/01.HYP.0000164570.20420.67. View

Afendy A, Kallman J, Stepanova M, Younoszai Z, Aquino R, Bianchi G . Predictors of health-related quality of life in patients with chronic liver disease. Aliment Pharmacol Ther. 2009; 30(5):469-76. DOI: 10.1111/j.1365-2036.2009.04061.x. View

Ahn S, Jang K, Won Jun D, Lee B, Shin K . Expression of liver X receptor correlates with intrahepatic inflammation and fibrosis in patients with nonalcoholic fatty liver disease. Dig Dis Sci. 2014; 59(12):2975-82. DOI: 10.1007/s10620-014-3289-x. View

Ahrens M, Ammerpohl O, von Schonfels W, Kolarova J, Bens S, Itzel T . DNA methylation analysis in nonalcoholic fatty liver disease suggests distinct disease-specific and remodeling signatures after bariatric surgery. Cell Metab. 2013; 18(2):296-302. DOI: 10.1016/j.cmet.2013.07.004. View

Airaghi L, Rango M, Maira D, Barbieri V, Valenti L, Lombardi R . Subclinical cerebrovascular disease in NAFLD without overt risk factors for atherosclerosis. Atherosclerosis. 2017; 268:27-31. DOI: 10.1016/j.atherosclerosis.2017.11.012. View

Albillos A, Lario M, Alvarez-Mon M . Cirrhosis-associated immune dysfunction: distinctive features and clinical relevance. J Hepatol. 2014; 61(6):1385-96. DOI: 10.1016/j.jhep.2014.08.010. View

Amores-Iniesta J, Barbera-Cremades M, Martinez C, Pons J, Revilla-Nuin B, Martinez-Alarcon L . Extracellular ATP Activates the NLRP3 Inflammasome and Is an Early Danger Signal of Skin Allograft Rejection. Cell Rep. 2017; 21(12):3414-3426. PMC: 5746605. DOI: 10.1016/j.celrep.2017.11.079. View

Angulo P . Nonalcoholic fatty liver disease. N Engl J Med. 2002; 346(16):1221-31. DOI: 10.1056/NEJMra011775. View

10.

Angulo P, Kleiner D, Dam-Larsen S, Adams L, Bjornsson E, Charatcharoenwitthaya P . Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology. 2015; 149(2):389-97.e10. PMC: 4516664. DOI: 10.1053/j.gastro.2015.04.043. View

11.

Anstee Q, Day C . The genetics of NAFLD. Nat Rev Gastroenterol Hepatol. 2013; 10(11):645-55. DOI: 10.1038/nrgastro.2013.182. View

12.

Araki O, Ying H, Zhu X, Willingham M, Cheng S . Distinct dysregulation of lipid metabolism by unliganded thyroid hormone receptor isoforms. Mol Endocrinol. 2009; 23(3):308-15. PMC: 2654517. DOI: 10.1210/me.2008-0311. View

13.

Armstrong M, Gaunt P, Aithal G, Barton D, Hull D, Parker R . Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet. 2015; 387(10019):679-690. DOI: 10.1016/S0140-6736(15)00803-X. View

14.

Artwohl M, Lindenmair A, Sexl V, Maier C, Rainer G, Freudenthaler A . Different mechanisms of saturated versus polyunsaturated FFA-induced apoptosis in human endothelial cells. J Lipid Res. 2008; 49(12):2627-40. DOI: 10.1194/jlr.M800393-JLR200. View

15.

Ashraf N, Sheikh T . Endoplasmic reticulum stress and Oxidative stress in the pathogenesis of Non-alcoholic fatty liver disease. Free Radic Res. 2015; 49(12):1405-18. DOI: 10.3109/10715762.2015.1078461. View

16.

Asrih M, Jornayvaz F . Diets and nonalcoholic fatty liver disease: the good and the bad. Clin Nutr. 2013; 33(2):186-90. DOI: 10.1016/j.clnu.2013.11.003. View

17.

Balboa E, Castro J, Pinochet M, Cancino G, Matias N, Saez P . MLN64 induces mitochondrial dysfunction associated with increased mitochondrial cholesterol content. Redox Biol. 2017; 12:274-284. PMC: 5344325. DOI: 10.1016/j.redox.2017.02.024. View

18.

Barber M, Price N, Travers M . Structure and regulation of acetyl-CoA carboxylase genes of metazoa. Biochim Biophys Acta. 2005; 1733(1):1-28. DOI: 10.1016/j.bbalip.2004.12.001. View

19.

Barbero-Camps E, Fernandez A, Baulies A, Martinez L, Fernandez-Checa J, Colell A . Endoplasmic reticulum stress mediates amyloid β neurotoxicity via mitochondrial cholesterol trafficking. Am J Pathol. 2014; 184(7):2066-81. PMC: 4076561. DOI: 10.1016/j.ajpath.2014.03.014. View

20.

Basaranoglu M, Basaranoglu G, Bugianesi E . Carbohydrate intake and nonalcoholic fatty liver disease: fructose as a weapon of mass destruction. Hepatobiliary Surg Nutr. 2015; 4(2):109-16. PMC: 4405421. DOI: 10.3978/j.issn.2304-3881.2014.11.05. View